发明授权
EP1098639B1 USE OF THE GLUCOSE UPTAKE ENHANCER ROSIGLITAZONE FOR REDUCING ISCHAEMIA-INDUCED APOPTOSIS OF PANCREATIC BETA CELLS, ENDOTHELIAL CELLS AND NEURONAL CELLS
有权
使用放大器葡萄糖RECORD罗格列酮，以减少缺血诱导的凋亡内皮细胞和神经细胞的胰腺β细胞
- 专利标题： USE OF THE GLUCOSE UPTAKE ENHANCER ROSIGLITAZONE FOR REDUCING ISCHAEMIA-INDUCED APOPTOSIS OF PANCREATIC BETA CELLS, ENDOTHELIAL CELLS AND NEURONAL CELLS
- 专利标题（中）： 使用放大器葡萄糖RECORD罗格列酮，以减少缺血诱导的凋亡内皮细胞和神经细胞的胰腺β细胞
-
申请号： EP99934914.5申请日： 1999-07-21
-
公开(公告)号： EP1098639B1公开(公告)日： 2005-02-09
- 发明人: BRIL, Antoine, M. A. , BUCKINGHAM, Robin, Edwin , KHANDOUDI, Nassirah
- 申请人： SmithKline Beecham plc , Laboratoire GlaxoSmithKline S.A.S.
- 申请人地址： 980 Great West Road Brentford, Middlesex TW8 9GS GB
- 专利权人： SmithKline Beecham plc,Laboratoire GlaxoSmithKline S.A.S.
- 当前专利权人： SmithKline Beecham plc,Laboratoire GlaxoSmithKline S.A.S.
- 当前专利权人地址： 980 Great West Road Brentford, Middlesex TW8 9GS GB
- 代理机构： Rutter, Keith, Dr.
- 优先权： GB9815871 19980721; GB9815872 19980721; GB9905387 19990309
- 国际公布： WO2000004890 20000203
- 主分类号： A61K31/00
- IPC分类号： A61K31/00 ; A61K31/425 ; A61K31/44 ; A61P9/10
摘要：
A method for reducing or preventing apoptosis of differentiated cells selected from the list consisting of cardiac myocytes, pancreatic beta cells, endothelial cells and neuronal cells in the human or non-human mammal, which method comprises administration, including acute administration, of an effective, non-toxic amount of a glucose uptake enhancer to a human or non-human mammal in need thereof.
公开/授权文献
- EP1098639A1 USE OF A GLUCOSE UPTAKE ENHANCER FOR REDUCING APOPTOSIS 公开/授权日：2001-05-16
信息查询
